NANOPRECIPITATION TECHNIQUE FOR PREPARATION OF STERICALLY STABILIZED RISPERIDONE NANOSUSPENSION: IN VITRO AND IN VIVO STUDY
Keywords:
Risperidone, nanosuspension, Pluronic F127, nanoprecipitation, bioavailabilityAbstract
Objective: Risperidone is an atypical antipsychotic drug used to treat schizophrenia; however it suffers from a poor aqueous solubility, which delays its onset of action. Therefore, the purpose of the present study is to utilize the nanotechnology to formulate nanoparticles that enhance the dissolution and hence the bioavailability of risperidone.
Methods: Nanosuspensions were prepared by nano precipitation method in the presence of selected stabilizers at different concentrations. The nanosuspensions were evaluated for their particle size, zeta potential, drug content and In vitro drug dissolution. The selected formula was freeze dried and characterized by scanning electron microscopy (SEM), fourier transforms infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffractometry studies (XRD) and pharmacokinetic study.
Results: The in vitro dissolution showed higher drug release compared to the pure drug. The optimum formula has an average particle size of 215.56±12.65 nm and zeta potential of-19.84±2.55mV. The bioavailability parameters in the rabbits were enhanced by 2 folds when compared with the marketed tablets (Risperidal®).
Conclusion: Nanoprecipitation method was successfully employed to produce stable risperidone nanosuspension by using the proper stabilizer (pluronic F 127). Risperidone nanoparticles may be a promising formula that improves the dissolution and hence oral bioavailability of poorly water soluble risperidone.
Keywords: Risperidone, Nanosuspension, Pluronic F127, Nanoprecipitation, Bioavailability
Downloads
References
Megens F, Awouters L, Schotte A. Survey on the pharmacodynamics of the dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685–93.
Anthony D, Nick C, Patel M, Lynn C. Antipsychotic drugs. Clin Ther 2004;26:649-66.
Leysen JE, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661–70.
Bronstein AC, Spyker DA, Cantilena LR. Annual report of the American association of poison control centers' national poison data system (NPDS), 27th annual report. Clin Toxicol 2010;48:979.
Megens F, Awouters HL, Schotte A. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994;114:9–23.
Martindale, The complete drug reference. SC Sweetman. Editor. Pharmaceutical Press: London, Chicago; 2009. p. 1024-7.
White SR. Acute dystonic reaction and the neuroleptic malignant syndrome. J Pharm Practice 2005;18:175-83.
Janssen CJ, Niemegeers F, Awouters KH, Schellekens A, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and GG and Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995;125:309-13.
Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspensions. Eur J Pharm Biopharm 2004;58:615-9.
Wongmekiat A, Tozuka Y, Oguchi T, Yamamoto K. Formation of fine drug particles by co-grinding with cyclodextrin. I. the use of β-cyclodextrin anhydrate and hydrate. Pharm Res 2002;19:1867-72.
Itoh K, Pongpeerapat A, Tozuka Y, Oguchi T, Yamamoto K. Nanoparticle formation of poorly water soluble drugs from ternary ground mixtures with PVP and SDS. Chem Pharm Bull 2003;51:171-4.
Vikram M, Jayvadan K, Dhaval J. Formulation, Optimization and characterization of simvastatin nanosuspension prepared by nanoprecipitation technique. Der Pharm Lett 2011;3:129-40.
Kipp JE, Wong J, Doty M, Werling J, Rebbeck C, Brynjelsen S. Method for preparing submicron particle suspensions. US Patent, 0031719 A1; 2003.
Matteucci ME, Brettmann BK, Rogers TL, Elder EJ, Williams RO, Johnston KP. The design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol Pharm 2007;4:782–93.
Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high-pressure homogenization. Eur J Pharm Biopharm 2006;62:3-16.
Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery, and release kinetics. J Controlled Release 2002;83:389-400.
Kumar MP, Rao YM, Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr Nanosci 2008;4:53-8.
Zhang D, Tan T, Gao L, Zhao W, Wang P. Preparation of azithromycin nanosuspensions by high-pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 2007:33:569-75.
Rahman Z, Zidan AS, Khan MA. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. Int J Pharm 2010;400;49-58.
Harkness JE WJ. The biology and medicine of rabbits and rodents. 3rd Edition. Lea and Febiger, Philadelphia; 1989.
Rajan S. A simple sample preparation with HPLC-UV method for estimation of amlodipine from plasma: application to bioequivalence study. Open Chem Biomed Methods J 2008;1:22-7.
Peter G, Francis LS, Shrikant V. Dighe. Pharmaceutical Bioequivalence. Drugs and the Pharmaceutical Sciences. New York, N. M. D; 1991. p. 48.
Gao L, Zhang D, Chen M, Zheng T, Wang S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm 2007;33:1332-9.
Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179-86.
Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci 2009;98:2091-103.
Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L. Peltier N, et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996;13:272-8.
Merisko E, Liversidge G, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113-20.
Kabalnov AS, Pertzov AV, Shchukin ED. Ostwald ripening in emulsions: I. Direct observations of Ostwald ripening in emulsions. Colloids Surfactant 1987;118:590–7.
Patravale VB. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004;56:827-40.
Saindane. Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. AAPS PharmSciTech 2013;14:189-99.
Vikram M. Formulation, Optimization, and characterization of simvastatin nanosuspension prepared by nanoprecipitation technique. Pharm Lett 2011;3:129-40.
Eerdenbrugh VB. Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions a case study with itraconazole. Eur J Pharm Biopharm 2008;70:590-6.
Wei L, Yonggang Y, Yongshou T, Xinlan X, Yang C, Liwei M, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm 2011;408:157–62.
Shivanand Pandey. Itraconazole nanosuspension meant for oral use: development of formulation, characterization and in vitro comparison with some marketed formulations. Pharm Lett 2010;2:162-71.